DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
A single citable reference for GLP-1 usage, efficacy, cost, adherence, and regulatory data. Every figure carries its source and year. Journalists and researchers: cite freely with attribution to LoseLab.
of US adults have taken a GLP-1 medication
Source: KFF Health Tracking Poll, 2024
US adults report having used a GLP-1 drug at some point
Source: KFF, 2024
of US adults are currently taking a GLP-1
Source: KFF, 2024
mean body weight loss on semaglutide 2.4 mg at 68 weeks
Source: STEP-1, NEJM, 2021
mean body weight loss on tirzepatide 15 mg at 72 weeks
Source: SURMOUNT-1, NEJM, 2022
mean body weight loss on retatrutide 12 mg at 80 weeks (Phase 3 topline)
Source: TRIUMPH-1, Eli Lilly, 2026
reduction in major cardiovascular events on semaglutide (established CVD, no diabetes)
Source: SELECT, NEJM, 2023
reduction in major kidney events on semaglutide in T2D + CKD
Source: FLOW, NEJM, 2024
NovoCare Direct cash-pay price for Wegovy
Source: Novo Nordisk, 2026
LillyDirect cash-pay vial price for Zepbound
Source: Eli Lilly, 2026
Medicare GLP-1 Bridge copay (launches July 1, 2026)
Source: CMS, 2026
typical US retail list price per month without insurance or manufacturer card
Source: manufacturer list pricing, 2026
of patients still taking their GLP-1 at 12 months
Source: NPR / real-world claims analysis, 2026
of patients who stop a GLP-1 plan to restart it
Source: NPR reporting, 2026
of lost weight regained within 1 year of stopping semaglutide
Source: STEP-4, JAMA, 2021
of STEP-1 participants reported nausea (vs 16% placebo)
Source: STEP-1, NEJM, 2021
first-round insurance prior-authorization appeal success rate (well-documented cases)
Source: editorial analysis of plan data, 2026
FDA public comment deadline on proposed 503B GLP-1 compounding ban
Source: FDA / Regulations.gov, 2026
FDA confirmed semaglutide + tirzepatide shortages resolved
Source: FDA Drug Shortage Database, 2026
oral GLP-1s FDA-approved between Dec 2025 and May 2026 (Foundayo, Wegovy pill, Ozempic pill)
Source: FDA approvals, 2026
LoseLab. “GLP-1 Statistics 2026.” loselab.com/glp1-statistics. Updated 2026-05-28. Each figure attributed to its primary source above.
Editorial aggregation of published data. Figures reflect the cited sources at the date of last update; primary sources are authoritative. Not medical advice.